STOCK TITAN

Quantum-Si Incorporated 8-K Filings

QSIAW NASDAQ

Every 8-K that Quantum-Si Incorporated (QSIAW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 8-K covers material events a company has to report between its quarterly reports, so if you follow QSIAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QSIAW filings page.

Rhea-AI Summary

Quantum-Si, Incorporated entered a new long-term lease for approximately 54,374 square feet of planned office, laboratory and manufacturing space in San Diego, California. The 10-year term is expected to begin around September 1, 2027, with a latest possible start of November 1, 2027.

Initial monthly base rent is about $315,369.20, or $5.80 per square foot, increasing roughly 3% each year. Base rent is fully abated for the first 20 months after commencement. The landlord will provide up to $17,127,810 as a tenant improvement allowance, while Quantum-Si pays prepaid rent of $434,448.26 and posts a $2,085,786.64 letter-of-credit security deposit. The lease supports ongoing development of the Proteus™ platform and expanded manufacturing capabilities and replaces existing San Diego space expected to expire on December 31, 2027.

Rhea-AI Summary

-SI Incorporated reported voting results from its Annual Meeting held on May 15, 2026. Shareholders representing approximately 84.59% of the total voting power of Class A and Class B shares formed a quorum.

All nominated directors were reelected, with Jonathan M. Rothberg, Ph.D. receiving 454,010,014 votes for and 429,631 against. Shareholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm, with 502,452,749 votes for, and approved the advisory vote on executive compensation with 441,315,119 votes for.

Rhea-AI Summary

Quantum-Si Incorporated reported first quarter 2026 results and updated its 2026 outlook. Revenue for the quarter was $258,000, generating gross profit of $74,000 and a gross margin of 29%. Net loss was $21.7 million, while adjusted EBITDA was negative $20.1 million.

Adjusted total operating expenses were $21.4 million, down from $22.9 million a year earlier as the company managed selling, general and administrative costs while increasing research and development for its Proteus platform. Cash, cash equivalents and marketable securities totaled $190.4 million as of March 31, 2026, which the company anticipates will fund operations into the second quarter of 2028.

For full-year 2026, Quantum-Si reiterated guidance of approximately $1.0 million in revenue, adjusted total operating expenses of $98.0 million or less, and total cash usage of $93.0 million or less, reflecting a transition year focused on preparing the Proteus single-molecule protein sequencing system for an anticipated commercial launch at the end of 2026.

Rhea-AI Summary

Quantum-Si Incorporated reported wider full-year losses while preparing for its next-generation Proteus platform launch. For 2025, revenue was $2.4 million, with gross profit of $1.2 million and a gross margin of 47%. The company posted a 2025 net loss of $101.3 million, similar to the prior year, but reduced adjusted operating expenses to $86.3 million from $99.0 million.

In the fourth quarter of 2025, revenue was $0.5 million with a 27% gross margin and a net loss of $17.6 million. Management highlighted significant cost discipline and one-time litigation charges of $18.7 million during 2025. As of December 31, 2025, cash, cash equivalents and marketable securities totaled $215.8 million, which the company believes funds operations into the second quarter of 2028.

For 2026, Quantum-Si issued guidance for revenue of approximately $1.0 million, adjusted total operating expenses of $98.0 million or less, and total cash usage of $93.0 million or less. The company expects 2026 to be a transition year, intentionally moderating revenue as it embeds upgrade credits and placement programs to support a stronger commercial launch of the Proteus system, which has a list price of $425,000 and is targeted for launch by the end of 2026.